15.64 USD
-0.41 (-2.55%)
15.64 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to JBIO. JBIO was compared to 525 industry peers in the Biotechnology industry. While JBIO has a great health rating, there are worries on its profitability. JBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- JBIO had negative earnings in the past year.
- JBIO had a negative operating cash flow in the past year.
- JBIO had negative earnings in each of the past 5 years.
- JBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -32.23%, JBIO is in the better half of the industry, outperforming 64.76% of the companies in the same industry.
- The Return On Equity of JBIO (-36.39%) is better than 72.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.23% | ||
| ROE | -36.39% | ||
| ROIC | N/A |
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- JBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for JBIO has been increased compared to 1 year ago.
- JBIO has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for JBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- JBIO has an Altman-Z score of 17.70. This indicates that JBIO is financially healthy and has little risk of bankruptcy at the moment.
- JBIO's Altman-Z score of 17.70 is amongst the best of the industry. JBIO outperforms 88.19% of its industry peers.
- There is no outstanding debt for JBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.7 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- JBIO has a Current Ratio of 9.01. This indicates that JBIO is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 9.01, JBIO is doing good in the industry, outperforming 78.67% of the companies in the same industry.
- A Quick Ratio of 9.01 indicates that JBIO has no problem at all paying its short term obligations.
- JBIO has a better Quick ratio (9.01) than 78.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.01 | ||
| Quick Ratio | 9.01 |
3. Growth
3.1 Past
- JBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.35%, which is quite impressive.
EPS 1Y (TTM)89.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 14.45% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.51%
EPS Next 2Y40.6%
EPS Next 3Y25.47%
EPS Next 5Y14.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- JBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as JBIO's earnings are expected to grow with 25.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.6%
EPS Next 3Y25.47%
5. Dividend
5.1 Amount
- JBIO has a Yearly Dividend Yield of 515.18%, which is a nice return.
- JBIO's Dividend Yield is rather good when compared to the industry average which is at 1.08. JBIO pays more dividend than 100.00% of the companies in the same industry.
- JBIO's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 515.18% |
5.2 History
- JBIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y40.6%
EPS Next 3Y25.47%
JADE BIOSCIENCES INC / JBIO FAQ
What is the fundamental rating for JBIO stock?
ChartMill assigns a fundamental rating of 3 / 10 to JBIO.
What is the valuation status for JBIO stock?
ChartMill assigns a valuation rating of 1 / 10 to JADE BIOSCIENCES INC (JBIO). This can be considered as Overvalued.
Can you provide the profitability details for JADE BIOSCIENCES INC?
JADE BIOSCIENCES INC (JBIO) has a profitability rating of 1 / 10.
Can you provide the financial health for JBIO stock?
The financial health rating of JADE BIOSCIENCES INC (JBIO) is 8 / 10.